ATE315230T1 - Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren - Google Patents

Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren

Info

Publication number
ATE315230T1
ATE315230T1 AT00953560T AT00953560T ATE315230T1 AT E315230 T1 ATE315230 T1 AT E315230T1 AT 00953560 T AT00953560 T AT 00953560T AT 00953560 T AT00953560 T AT 00953560T AT E315230 T1 ATE315230 T1 AT E315230T1
Authority
AT
Austria
Prior art keywords
identifying
prostaglandin
receptor
receptor modulators
test substance
Prior art date
Application number
AT00953560T
Other languages
English (en)
Inventor
Hiroyuki Hirai
Kazuyuki Ogawa
Kinya Nagata
Syoichi Takano
Original Assignee
Bml Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bml Inc filed Critical Bml Inc
Application granted granted Critical
Publication of ATE315230T1 publication Critical patent/ATE315230T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00953560T 1999-08-23 2000-08-22 Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren ATE315230T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23620799 1999-08-23
JP2000153172 2000-05-24

Publications (1)

Publication Number Publication Date
ATE315230T1 true ATE315230T1 (de) 2006-02-15

Family

ID=26532542

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00953560T ATE315230T1 (de) 1999-08-23 2000-08-22 Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren

Country Status (9)

Country Link
US (1) US6884593B1 (de)
EP (1) EP1211513B1 (de)
JP (1) JP3486408B2 (de)
AT (1) ATE315230T1 (de)
AU (1) AU772121B2 (de)
CA (1) CA2383135C (de)
DE (2) DE1211513T1 (de)
NO (1) NO20020837L (de)
WO (1) WO2001014882A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
JP2005508164A (ja) * 2001-10-10 2005-03-31 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ２１１３２、ヒトｇタンパク質共役レセプターファミリーメンバーおよびそれらの使用
WO2003097042A1 (en) * 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Pgd2 receptor antagonist
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
PL377314A1 (pl) 2002-12-20 2006-01-23 Amgen Inc. Modulatory astmy i zapaleń na tle alergicznym
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
MXPA06011891A (es) * 2004-04-20 2007-04-24 Pfizer Metodo para tratar el dolor neuropatico.
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
UY29223A1 (es) 2004-11-23 2006-06-30 Astrazeneca Ab Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
EP1937632A1 (de) 2005-10-06 2008-07-02 Astra Zeneca AB Neue verbindungen
CA2658496A1 (en) 2006-07-22 2008-01-31 Oxagen Limited 2-{5-fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1h-indol-yl} acetic acid derivatives and esters thereof having crth2 antagonist activity
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
WO2009061676A2 (en) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
US20100298368A1 (en) * 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
ES2471919T3 (es) 2007-12-19 2014-06-27 Amgen, Inc Derivados de ácido fenilac�tico como moduladores de inflamación
CA2712017C (en) 2008-01-18 2016-08-09 Oxagen Limited Compounds having crth2 antagonist activity
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
WO2009099901A1 (en) * 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2009102893A2 (en) * 2008-02-14 2009-08-20 Amira Pharmaceuticals, Inc. CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
JP2011513242A (ja) * 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
US8426449B2 (en) * 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US8071807B2 (en) 2008-07-03 2011-12-06 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
EP2461809A4 (de) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc Pharmazeutische zusammensetzungen für die augen aus dp2-rezeptor-antagonisten
US8815917B2 (en) * 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
EP2521713A4 (de) 2010-01-06 2013-10-02 Panmira Pharmaceuticals Llc Dp2-antagonist und seine verwendung
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
ES2690782T3 (es) 2012-10-24 2018-11-22 Nyu Winthrop Hospital Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
CA3075688A1 (en) 2017-09-13 2019-03-21 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
EP4070113A4 (de) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Beurteilung von präeklampsie unter verwendung von tests für freien und dissoziierten plazentalen wachstumsfaktor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046677A1 (fr) * 1996-06-05 1997-12-11 Bml, Inc. PROTEINE SPECIFIQUE DU Th2 HUMAIN, GENE (B19) CODANT POUR CETTE PROTEINE, TRANSFORMANT, VECTEUR DE RECOMBINAISON ET ANTICORPS MONOCLONAL S'Y RAPPORTANT
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2

Also Published As

Publication number Publication date
US6884593B1 (en) 2005-04-26
CA2383135C (en) 2010-11-30
EP1211513A1 (de) 2002-06-05
DE60025368T2 (de) 2006-09-14
AU6598800A (en) 2001-03-19
CA2383135A1 (en) 2001-03-01
EP1211513B1 (de) 2006-01-04
JP3486408B2 (ja) 2004-01-13
WO2001014882A1 (fr) 2001-03-01
NO20020837D0 (no) 2002-02-20
EP1211513A4 (de) 2003-04-16
AU772121B2 (en) 2004-04-08
NO20020837L (no) 2002-04-22
DE1211513T1 (de) 2002-11-14
DE60025368D1 (de) 2006-03-30

Similar Documents

Publication Publication Date Title
ATE315230T1 (de) Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren
DE69842134D1 (de) Elektronische verfahren und vorrichtung zum nachweis von analyten
DE60328870D1 (de) Verfahren zur modulierung von cd200-rezeptoren
ATE538594T1 (de) Verfahren und vorrichtung zur erweiterung des dynamikbereiches eines projektionssystems
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
DE50001043D1 (de) Verfahren und vorrichtung zum herstellen von verschleissfesten, tribologischen zylinderlaufflächen
DE69729253D1 (de) Verfahren und Vorrichtung zum Beschichten von chirurgischem Nahtmaterial
ATE283830T1 (de) Verfahren zur behandlung von glassubstraten und glassubstraten zur herstellung von anzeigeschirmen
EP1099102A4 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60216559D1 (de) Verfahren und Vorrichtung zur Frequenzmultiplexierung mit Ausgleich von Interferenzen
DE69633312D1 (de) Verfahren zur Verbesserung der Verschleissfestigkeit von biokompatiblen Polymerkomponenten
DE50008476D1 (de) Verfahren und Vorrichtung zum Einstellen von pH+-Werten und Redoxpotentialen von Flüssigkeiten mittels Elektrolyse
DE69827066D1 (de) Verfahren und Vorrichtung zum Kompensieren von Mehrkanalechos
ATE413490T1 (de) Verfahren und vorrichtung zur gezielten applizierung von leistungsfördernden stoffen auf einen kreppzylinder
DE59812896D1 (de) Vorrichtung zum optischen prüfen von oberflächen
ATE260678T1 (de) Verfahren zur detektion von endometriosis
ATE397098T1 (de) Verfahren zur diagnostik von eierstock endometriose
DE60235211D1 (de) Verfahren zum Vorlöschen von Rauschen eines Bildes.
DE69600473D1 (de) Ascorbatbeständiges Verfahren zum Nachweis von Wasserstoffperoxid
ATE403864T1 (de) Verfahren zur identifizierung von substanzen, die die aktivität von hyperpolarisations-aktivierten kationen-kanälen modulieren
DE69824839D1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren
BG102064A (en) Method for increasing the retinal blood circulation
DE69937733D1 (de) Verfahren und vorrichtung zur steuerbaren versorgung von hydraulischem druckmittel
ATE329306T1 (de) Verfahren und vorrichtung zum erzeugen einer pseudozufallsfolge mittels diskretem logarithmus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties